Journal Article

Identification of NS2B-NS3 Protease Inhibitors for Therapeutic Application in ZIKV Infection: A Pharmacophore-Based High-Throughput Virtual Screening and MD Simulations Approaches

Ali, Muhammad Akhtar, Irfan, Muhammad, Hussain, Nadia, Sajjad, Muhammad, Saleem, Mahjabeen, Ghani, Muhammad Usman, Gul, Roquyya, Naveed, Muhammad, Al Haddad, Amal H. I., Said, Amira S. A., Rehman, Hafiz Muzzammel, Bhinder, Munir Ahmad

2023

Overview

Zika virus (ZIKV) pandemic and its implication in congenital malformations and severe neurological disorders had created serious threats to global health. ZIKV is a mosquito-borne flavivirus which spread rapidly and infect a large number of people in a shorter time-span. Due to the lack of effective therapeutics, this had become paramount urgency to discover effective drug molecules to encounter the viral infection. Various anti-ZIKV drug discovery efforts during the past several years had been unsuccessful to develop an effective cure. The NS2B-NS3 protein was reported as an attractive therapeutic target for inhibiting viral proliferation, due to its central role in viral replication and maturation of non-structural viral proteins. Therefore, the current in silico drug exploration aimed to identify the novel inhibitors of Zika NS2B-NS3 protease by implementing an e-pharmacophore-based high-throughput virtual screening. A 3D e-pharmacophore model was generated based on the five-featured (ADPRR) pharmacophore hypothesis. Subsequently, the predicted model is further subjected to the high-throughput virtual screening to reveal top hit molecules from the various small molecule databases. Initial hits were examined in terms of binding free energies and ADME properties to identify the candidate hit exhibiting a favourable pharmacokinetic profile. Eventually, molecular dynamic (MD) simulations studies were conducted to evaluate the binding stability of the hit molecule inside the receptor cavity. The findings of the in silico analysis manifested affirmative evidence for three hit molecules with −64.28, −55.15 and −50.16 kcal/mol binding free energies, as potent inhibitors of Zika NS2B-NS3 protease. Hence, these molecules holds the promising potential to serve as a prospective candidates to design effective drugs against ZIKV and related viral infections.

• Publisher: MDPI AG,MDPI
• Subject: ASINEX database / Binding / Congenital defects / Crystal structure / Dengue fever / Drug development / Dynamic stability / e-pharmacophore approach / Encephalitis / Energy / Global health / high-throughput virtual screening / Hydrogen bonds / Ligands / Metabolism / Molecular dynamics / molecular dynamics simulation / Neurological diseases / NS3 protein / Pandemics / Pharmacokinetics / Pharmacology / Polypeptides / prime MM-GBSA / Protease / Protease inhibitors / Proteinase inhibitors / Proteins / Public health / Screening / Stability analysis / Therapeutic targets / Three dimensional models / Vector-borne diseases / Vectors (Biology) / Viral infections / West Nile virus / Zika virus